Education
About Us
Working with TipRanks
Follow Us
Aim Immunotech Inc. (AIM)
:AIM
Top Page
AIM ImmunoTech
(NYSE MKT:AIM)
Rating:39Underperform
Price Target:
$3.00
▲(6.01%Upside)
Positive Factors
Analyst Rating
The analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.
Clinical Trials
Positive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.
Negative Factors
Corporate Governance
Dissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.
Stock Listing
The company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.
AIM ImmunoTech (AIM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.16M
Dividend YieldN/A
Average Volume (3M)272.32K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth-24.35%
EPS Growth61.00%
CountryUS
Employees21
SectorHealthcare
Sector Strength38
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.00
Shares Outstanding764,188
10 Day Avg. Volume795,632
30 Day Avg. Volume272,320
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)-163.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap2.96
Enterprise Value/Revenue8.48
Enterprise Value/Gross Profit78.91
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$1.50Price Target Upside-47.00% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
AIM ImmunoTech Business Overview & Revenue Model
Company DescriptionAIM ImmunoTech (AIM) is a biotechnology company focused on the research and development of immuno-pharmacological therapies. The company's primary objective is to develop innovative treatments for immune disorders, viral diseases, and cancer. It is known for its flagship product, Ampligen, an experimental drug that serves as an immune modulator. AIM ImmunoTech operates primarily in the biotechnology and healthcare sectors, targeting unmet medical needs through its therapeutic solutions.
How the Company Makes MoneyAIM ImmunoTech generates revenue primarily through the development and commercialization of its proprietary drug, Ampligen. The company earns money by partnering with other pharmaceutical companies for the distribution and sale of Ampligen in various markets. Additionally, AIM engages in licensing agreements and collaborative research projects to fund and advance the clinical development of its therapies. The company also seeks government grants and clinical trial funding to support its research endeavors, which contributes to its revenue stream.
AIM ImmunoTech Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q4-2024)
| % Change Since: -67.66%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.Q4-2024 Updates
Positive Updates
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Leadership Expansion
The company strengthened its leadership with the addition of two Board members, Ted Kellner and David Chemerow, bringing extensive investment and financial expertise.
Approval for Phase 2 Pancreatic Cancer Trial
Continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial has been approved, with dosing commenced, marking a key advancement in this program.
Publication and Patent Advancements
A new U.S. patent was granted for the treatment of endometriosis, and a Netherlands patent for post-COVID fatigue. Also, new data was published from a study in early-stage triple negative breast cancer.
R&D Cost Reduction
Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating more efficient use of resources.
G&A Expenses Reduction
General and administrative expenses decreased from $21.1 million in 2023 to $13.7 million in 2024, reflecting improved operational efficiency.
Negative Updates
Low Cash Reserves
As of December 31, 2024, AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities, highlighting potential financial constraints.
Continued Listing Risk
The company is at risk of being delisted from the New York Stock Exchange American and is considering a reverse stock split to maintain compliance.
Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.AIM ImmunoTech Financial Statement Overview
Summary
AIM ImmunoTech is facing significant financial hurdles characterized by declining revenue, persistent losses, and negative cash flow. The company has managed its debt levels well with no debt, but the lack of equity and negative cash flow raise concerns about its long-term financial sustainability.Income Statement
AIM ImmunoTech has demonstrated declining revenue with negative net income over the past years. Despite a slight improvement in gross profit, EBIT and EBITDA margins remain negative, indicating ongoing operational challenges and a lack of profitability.20
Very Negative
Balance Sheet
The company has a strong cash position relative to its total assets, but it faces challenges with zero stockholders' equity, indicating potential financial distress. The absence of debt provides some stability, yet the lack of equity suggests limited growth capacity.30
Negative
Cash Flow
Operating cash flow remains negative, reflecting persistent cash burn. While the company has managed to secure financing, free cash flow remains negative, and growth in free cash flow is absent, indicating ongoing liquidity challenges.25
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 170.00K | 202.00K | 141.00K | 135.00K | 163.00K |
| Gross Profit | 139.00K | 160.00K | -19.78M | -715.00K | -643.00K |
| EBITDA | -16.49M | -31.68M | -19.87M | -18.25M | -13.02M |
| Net Income | -17.32M | -28.96M | -21.09M | -21.51M | -16.26M |
Balance Sheet | |||||
| Total Assets | 8.61M | 19.38M | 40.49M | 57.70M | 64.58M |
| Cash, Cash Equivalents and Short-Term Investments | 3.98M | 13.07M | 34.19M | 48.27M | 39.00M |
| Total Debt | 2.94M | 718.00K | 837.00K | 149.00K | 2.29M |
| Total Liabilities | 9.93M | 9.15M | 2.02M | 820.00K | 3.29M |
| Stockholders Equity | -1.32M | 10.23M | 38.47M | 56.88M | 61.29M |
Cash Flow | |||||
| Free Cash Flow | -14.91M | -21.85M | -16.38M | -14.60M | -10.96M |
| Operating Cash Flow | -14.89M | -21.27M | -16.11M | -13.96M | -10.37M |
| Investing Cash Flow | 4.71M | -832.00K | 10.99M | -631.00K | -9.16M |
| Financing Cash Flow | 6.44M | 485.00K | 80.00K | 8.19M | 56.56M |
AIM ImmunoTech Technical Analysis
Negative
2.83
Price Trends
8.06
Negative
8.42
Negative
14.39
Negative
Market Momentum
-1.34
Positive
19.39
Positive
0.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 2.83 is below the 20-day moving average (MA) of 7.60, below the 50-day MA of 8.06, and below the 200-day MA of 14.39, indicating a bearish trend. The MACD of -1.34 indicates Positive momentum. The RSI at 19.39 is Positive, neither overbought nor oversold. The STOCH value of 0.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.
AIM ImmunoTech Risk Analysis
AIM ImmunoTech disclosed 33 risk factors in its most recent earnings report. AIM ImmunoTech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AIM ImmunoTech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.35B | 0.50 | -65.61% | 2.47% | 15.28% | 1.44% | |
42 Neutral | $6.42M | ― | -233.67% | ― | ― | -1786.46% | |
39 Underperform | $2.16M | ― | -3138.91% | ― | -24.35% | 61.00% | |
34 Underperform | $5.70M | ― | -538.87% | ― | ― | -26.02% | |
29 Underperform | $8.46M | ― | -192.72% | ― | ― | 56.26% |
* Healthcare Sector Average
Performance Comparison
AIM
AIM ImmunoTech
2.83
-29.43
-91.23%
GTBP
GT Biopharma
1.81
-0.52
-22.32%
PCSA
Processa Pharmaceuticals
0.21
-1.57
-88.20%
APLM
Apollomics
5.87
-10.07
-63.17%
AIM ImmunoTech Corporate Events
Private Placements and Financing
AIM ImmunoTech Closes $8 Million Public Offering
Positive
Jul 31, 2025
On July 31, 2025, AIM ImmunoTech Inc. announced the closing of its public offering, raising approximately $8.0 million through the sale of 2,000,000 shares of common stock and accompanying warrants. The offering, managed by Maxim Group LLC, is expected to bolster the company’s financial position, potentially enhancing its ability to advance its therapeutic developments.
The most recent analyst rating on (AIM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Product-Related AnnouncementsBusiness Operations and Strategy
AIM ImmunoTech Reports Positive Phase 2 Study Results
Positive
Jul 28, 2025
On July 28, 2025, AIM ImmunoTech Inc. announced positive data from its ongoing Phase 2 DURIPANC study, which evaluates the combination of its drug Ampligen® with AstraZeneca’s Imfinzi® for treating metastatic pancreatic cancer. The study, a collaboration with AstraZeneca and Erasmus Medical Center, has shown promising results with no significant toxicity and improved progression-free and overall survival rates. This development suggests a potential benefit in combining Ampligen’s selective innate immune activation with durvalumab’s checkpoint inhibition, offering hope for a new therapy in pancreatic cancer maintenance.
The most recent analyst rating on (AIM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Delistings and Listing ChangesRegulatory Filings and Compliance
AIM ImmunoTech Faces NYSE Noncompliance Notification
Negative
Jun 20, 2025
On June 17, 2025, AIM ImmunoTech Inc. received a notification from NYSE American LLC indicating noncompliance with the minimum stockholders’ equity requirements due to a stockholders’ deficit of negative $3.9 million as of March 31, 2025, and consistent losses over the past five fiscal years. Despite a previous warning in December 2024, the company has until June 11, 2026, to regain compliance, and its stock continues to trade on the NYSE American. The notification does not impact the company’s operations or SEC reporting requirements.
The most recent analyst rating on (AIM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.